BioSpace News Archive

The U.K authorized AstraZeneca’s COVID-19 vaccine on Wednesday, but it could be April at the earliest before the drug will likely be administered in the United States, Operation Warp Speed’s chief said.

From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.

Seattle-based Madrona Venture Group closed $500 million in new funds that will be used to accelerate startup tech and life science companies primarily in the Pacific Northwest.

BioSpace highlights a number of the key M&A deals struck over the past 12 months.

If 2020 taught us anything, it was that unexpected things happen. That said, there are some stories we’ll be watching for. Here’s a look.

It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

Axsome Therapeutics reported positive data from the long-term, open-label Phase III MOVEMENT trial of AXS-07 for the treatment of acute migraine.

ACCORD is the second pivotal trial of AXS-05 in Alzheimer’s disease agitation No treatments are currently approved for Alzheimer’s disease agitation

Thermo Fisher Scientific, the world leader in serving science, today announced it has completed the acquisition of Phitonex, Inc., a Durham, North Carolina -based company that has pioneered a spectral dye platform for high-resolution biology applications designed to accelerate research and development in cell therapy, immuno-onco